Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals, Inc. (PHAT)
:PHAT
PHAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.21 - $19.71
Previous CloseN/A
Volume285.74K
Average Volume (3M)962.79K
Market Cap
$585.04M
Enterprise Value$803.57M
Total Cash (Recent Filing)$212.31M
Total Debt (Recent Filing)$203.56M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Nov 06, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding69,814,120
10 Day Avg. Volume940,795
30 Day Avg. Volume962,794
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue9.82
Enterprise Value/Gross Profit11.38
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$21.50Price Target Upside148.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market ConfidenceInvestor sentiment following the NCE announcement demonstrated a vote of confidence, with PHAT shares closing up approximately 90%.
Product InnovationVOQUEZNA acts as a novel and differentiated potassium competitive acid blocker (PCAB) for GERD and NERD patients, representing the first innovation in GERD in decades.
Regulatory ApprovalFDA's decision to approve the company's Citizen's Petition and recognize Voquezna's full 10-year exclusivity removes a big overhang on the stock.
Bears Say
Leadership ChangesA number of C-suite changes were announced, including the departure of the COO, CCO, and CFO, effective within a few weeks.
Past Market VolatilityShares were severely punished—beyond what was the underlying value with only two years of exclusivity lost.
Price Target ReductionStrategic updates have led to a reduction in the price target from $28 to $20 per share.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $2.21 and its highest was $19.71 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $585.04M.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.95 by -$0.1.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 69,814,120 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.95. Following the earnings report the stock price went down -21.678%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (148.84% Upside)
$21.50 (148.84% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 395.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $202.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.29%
12-Months-Change
Fundamentals
Return on Equity
181.41%
Trailing 12-Months
Asset Growth
-17.47%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Phathom Pharmaceuticals is experiencing solid prescription growth and is making strides towards profitability through cost management. However, challenges such as stock price constraints, leadership transitions, and strategic promotional cutbacks underscore the need for careful navigation in the coming quarters.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$21.50
▲(148.84% Upside)
Technical Analysis
Rigel
―
Benitec Biopharma
―
Allogene Therapeutics
―
Entrada Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
11.16% Insiders
16.56% Mutual Funds
10.81% Other Institutional Investors
52.65% Public Companies and
Individual Investors